We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M Turnover 60.61%
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+2.11%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.4M
AUM Growth
+$8.29M
Cap. Flow
+$2.99M
Cap. Flow %
4.5%
Top 10 Hldgs %
32.21%
Holding
297
New
108
Increased
49
Reduced
51
Closed
72
Avg Time Held Equity + Options
0.5 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.1 years
Avg Time Held Equity only
0.5 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.2 years

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$3.53M
2
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$2.94M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$2.18M
4
ARAV
Aravive, Inc. Common Stock
ARAV
+$1.54M
5
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$1.37M

Top Sells

Rank Stock Value
1
GIS icon
General Mills
GIS
+$2.52M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$2.31M
3
AMGN icon
Amgen
AMGN
+$2.08M
4
ABT icon
Abbott
ABT
+$1.72M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$1.56M

Sector Composition

Rank Sector Weight
1 Healthcare 43.45%
2 Miscellaneous 41.8%
3 Consumer Discretionary 7.1%
4 Consumer Staples 6.25%
5 Communication Services 0.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GBT
276
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-20,000
Closed -$30K –
GBT
277
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-1,805
Closed -$49K –
GBT
278
PUT
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-20,000
Closed -$54K –
MNK
279
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-10,000
Closed -$448K –
MNK
280
PUT
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-7,700
Closed -$8K –
PTLA
281
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-46,100
Closed -$395K –
PTLA
282
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-41,187
Closed -$2.31M –
PTLA
283
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-122,300
Closed -$36K –
AGN
284
CALL
DELISTED
Allergan plc
AGN
– –
-7,500
Closed -$46K –
AGN
285
PUT
DELISTED
Allergan plc
AGN
– –
-12,000
Closed -$16K –
AKS
286
CALL
DELISTED
AK Steel Holding Corp
AKS
– –
-20,000
Closed -$2K –
MDCO
287
DELISTED
Medicines Co
MDCO
– –
-16,931
Closed -$644K –
MDCO
288
PUT
DELISTED
Medicines Co
MDCO
– –
-17,000
Closed -$295K –
IPCI
289
CALL
DELISTED
Intellipharmaceuticals International Inc.
IPCI
– –
-7,200
Closed -$23K –
PF
290
DELISTED
Pinnacle Foods, Inc.
PF
– –
-7,100
Closed -$421K –
WFM
291
CALL
DELISTED
Whole Foods Market Inc
WFM
– –
-21,400
Closed -$12K –
KATE
292
CALL
DELISTED
Kate Spade & Company
KATE
– –
-50,400
Closed -$6K –
KATE
293
DELISTED
Kate Spade & Company
KATE
– –
-300
Closed -$6K –
DISH
294
CALL
DELISTED
DISH Network Corp.
DISH
– –
-24,300
Closed -$17K –
NIHD
295
DELISTED
NII Holdings, Inc. Common Stock
NIHD
– –
-12,500
Closed -$10K –
CELG
296
DELISTED
Celgene Corp
CELG
– –
-5,000
Closed -$649K –
CELG
297
PUT
DELISTED
Celgene Corp
CELG
– –
-5,000
Closed -$13K –
8 9 10 11
12

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q3 2017 Portfolio in Review

As of Q3 2017, FT Options held 297 positions worth $66.4M, up 14% from $58.1M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

FT Options deployed $2.99M of net new capital in Q3 2017, opening 108 new positions and adding to 49 existing holdings. Its largest new stake was Incyte: 27,887 shares worth $3.26M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 43% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

On the sell side, the largest reduction was General Mills, an estimated $2.52M trimmed.

  • FT Options's largest Q3 2017 buy was Incyte: 27,887 shares worth $3.26M.
  • FT Options added most to Sio Gene Therapies Inc. Common Stock in Q3 2017, an estimated $1.37M increase.
  • FT Options's biggest Q3 2017 reduction was General Mills, cutting an estimated $2.52M.
  • FT Options fully exited Portola Pharmaceuticals, Inc. in Q3 2017, selling an estimated $2.31M.
  • FT Options's ten largest holdings make up 32% of its $66.4M portfolio in Q3 2017.
  • FT Options opened 108 new positions and closed 72 in Q3 2017.
  • FT Options's portfolio value rose 14% quarter-over-quarter to $66.4M.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.